| Literature DB >> 16884774 |
Fiona C Kimberley1, Baalasubramanian Sivasankar, B Paul Morgan.
Abstract
CD59 was first identified as a regulator of the terminal pathway of complement, which acts by binding to the C8/C9 components of the assembling membrane attack complex (MAC), to inhibit formation of the lytic pore. Structurally, CD59 is a small, highly glycosylated, GPI-linked protein, with a wide expression profile. Functionally, the role of CD59 in complement regulation is well-defined but studies have also shown clear evidence for signalling properties, which are linked to its glycophosphatidyl inositol (GPI) anchor and its location within lipid rafts. Cross-linking of CD59 using specific monoclonal antibodies drives both calcium release and activation of lipid-raft associated signalling molecules such as tyrosine kinases. These observations clearly show that CD59 exhibits roles independent of its function as a complement inhibitor. In this review, we examine the progression of research in this area and explore the alternative functions of CD59 that have recently been defined.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16884774 DOI: 10.1016/j.molimm.2006.06.019
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407